The role of norepinephrine (NE) in attention, memory, affect, stress, heart rate and blood pressure implicate NE in psychiatric and cardiovascular disease. The norepinephrine transporter (NET) mediates reuptake of released catecholamines, thus playing a role in the limitation of signaling strength, in the central and peripheral nervous systems. Nonsynonymous single nucleotide polymorphisms (SNPs) in the human NET (hNET) gene that influence transporter function can contribute to disease, such as the nonfunctional transporter, A457P, identified in Orthostatic Intolerance. Here, we examine additional amino acid variants that have been identified, but not characterized, in populations that include cardiovascular phenotypes. Variant hNETs were expressed in COS-7 cells and assayed for protein expression and trafficking using cell-surface biotinylation and Western blot analysis, transport of radiolabeled substrate, antagonist interaction and regulation through protein kinase C(PKC) linked-pathways by the phorbol ester, β-PMA. We observed functional perturbations in 6 out of the 10 mutants studied.
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systems in response to stress suggest that NE may play a role in disorders triggered by early life trauma, including depression and post-traumatic stress disorder (Heim and Nemeroff, 2001) . NE also plays an important role in attention, vigilance, learning, and memory and is hypothesized to contribute to Attention Deficit/Hyperactivity Disorder (ADHD) (Biederman and Spencer, 1999) .
Stimulant drugs used to treat ADHD act on both the NET and DA transporter (DAT) and atomoxetine, which selectively targets NET, is also effective in treating ADHD (Biederman and Spencer, 1999) . The activity of NET at postganglionic sympathetic nerve terminals, especially in the heart, is impacted in diseases of the cardiovascular system (Blakely, 2001; Hahn and Blakely, 2002a) . Diminished NE uptake sites and activity have been observed in hypertension, diabetes, cardiomyopathy and heart failure and ischemia-induced efflux of nonvesicular, cytoplasmic NE via NET may also contribute to fatal arrhythmias (Hahn and Blakely, 2002a) .
The importance of NET in the homeostasis of NE in brain and autonomic nervous system, evidence of its dysfunction in disease, and its role as a target for therapeutics raise the question of whether alterations in NE homeostasis or drug response derive from hNET genetic variation. A number of hNET promoter, intron, and coding region polymorphisms have been identified through both discovery-oriented studies of hNET in various clinical populations or during the course of genome sequencing efforts (Hahn and Blakely, 2002a) . To date, approximately 20 nonsynonymous single nucleotide polymorphisms (SNPs), which result in amino acid substitutions, have been reported in hNET. Many of these variants were derived from psychiatric and cardiovascular phenotypes, yet only a limited number has been examined for alterations in expression or function (Stöber et al., 1996; Halushka et al., 1999; Runkel et al., 2000; Iwasa et al., 2001) . Our laboratory identified, in a familial form of Orthostatic Intolerance, a nonsynymous hNET SNP that produces the protein variant, A457P, a loss of function, This article has not been copyedited and formatted. The final version may differ from this version.
Molecular Pharmacology Fast Forward. Published on May 13, 2005 as DOI: 10.1124 at ASPET Journals on October 20, 2017 molpharm.aspetjournals.org Downloaded from dominant-negative transporter that contributes to increased heart rate and plasma norepinephrine levels (Shannon et al., 2000; Hahn et al., 2003) . Overall, these findings suggest that cardiovascular phenotypes could be enriched for hNET SNPs that produce functional alterations.
In the present work, we examine the functional impact of amino acid variants, primarily found in cardiovascular phenotypes. We observe changes in protein expression levels, including aberrant processing by glycosylation and altered surface expression, with variants exhibiting abolished or greatly diminished plasma membrane expression. Furthermore, coexpression of hNET with variants exhibiting greatly altered processing generates a dominant negative impact on hNET expression and cell-surface targeting. We demonstrate changes in both NE and DA transport that reveal effects of variants on substrate selectivity. Finally, in a single variant, F528C, we observe both a shift in the potency of the tricyclic antidepressant, desipramine and a novel regulatory phenotype of resistance to regulation through PKC-mediated pathways.
MOL 11270 8 were begun ~24 hours after transfection. Observations in all experiments were obtained using multiple DNA stocks to control for any variability in DNA plasmid preparation.
[ 3 H]NE transport assays
Transport was assayed essentially as described (Hahn et al., 2003) . Briefly, cells were washed twice with Kreb's-Ringer's-HEPES (KRH; 120 mM NaCl, 4.7 mM KCl, 1.2 mM KH 2 PO4, 2.2 mM CaCl 2 , 10 mM HEPES, pH 7.4) buffer and preincubated with assay buffer (KRH, 10 mM D-glucose, 100 µM ascorbic acid, 100 µM pargyline and 1 mM tropolone) for 10 min at 37°C, with 1 µM desipramine added to a subset of wells to assess nonspecific accumulation, followed by the addition of radiolabeled substrate for a 10 min transport assay. In experiments using a single concentration of substrate, 50 nM of 
Cell surface biotinylation and immunoblots
To investigate the effect of hNET SNPs on protein expression and trafficking, cellsurface biotinylation was performed on intact cells (Hahn et al., 2003) . Cells were washed 4X in 1X PBS and incubated with 1.0 mg/ml sulfosuccinimidyl 2-(biotinamido)-ethyl-1, 3-dithiopropionate (sulfo-NHS-SS-biotin; Pierce Biotechnology, Inc., Rockford, IL) in PBS containing 0.1 mM CaCl 2 and 1.0 mM MgCl 2 (PBS/Ca/Mg) for 20 min at 4°C, washed, quenched with 3 washes of 100 mM glycine in PBS/Ca/Mg and washed 2 times in PBS/Ca/Mg.
Cells were lysed in radioimmunoprecipitation (RIPA) buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, 1% sodium deoxycholate, 250 µM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin and 1 µM pepstatin) for 30 min at 4°C, centrifuged at 20,000
x g for 30 min and supernatants were assayed for protein concentration using a BCA kit (Pierce).
Equal amounts of protein were incubated with Immunopure Immobilized Streptavidin beads (Pierce) for 45 min at RT. Beads were washed four times in RIPA buffer and proteins bound to beads were eluted in 1X sample buffer (62.5 mM Tris, pH 6.8, 20% glycerol, 2% SDS, 5% β-mercaptoethanol, and 0.01% bromophenol blue). Samples were then separated by 10% SDSThis article has not been copyedited and formatted. The final version may differ from this version. PAGE. Proteins were transferred electrophoretically to Immobilon-P membrane (Millipore, Bedford, MA). Membranes were incubated with a monoclonal antibody directed against hNET at a dilution of 1:500 (NET17-1; Mab Technologies, Inc., Stone Mountain, GA), followed by incubation with a goat anti-mouse peroxidase-conjugated secondary antibody at a dilution of 1:5000 (Jackson ImmunoResearch Laboratories Inc., West Grove, PA). In cotransfection experiments that utilized an HA-tagged hNET an HRP-conjugated anti-HA antibody was used at a dilution of 1:500 (Roche). Visualization of immunoreactivity was achieved using Western
Lightning enhanced chemiluminescent reagent (Perkin Elmer Life Sciences, Inc., Boston, MA).
Quantitation of Immunoblots
Quantitation of band density was performed on scanned images using ImageJ, a public domain image processing program (W. Rasband, NIMH, Bethesda, MD). The optical density of each lane was plotted and area under the curve measured for both the 110 and 54 kDa NET immunoreactive bands. Analyses were performed on replicate experiments and data are presented both in graph form of the means ± S.E.M. of repeated experiments and with blots of a representative experiment.
Statistical Analysis
Data were analyzed using one-way analysis of variance (ANOVA) with levels of significance set at p < 0.05 (SPSS for Windows, release 7.0). 
RESULTS
Multiple naturally-occurring variants have been identified in hNET, though only a few have been functionally assessed ( Fig. 1 ; Halushka et al., 1999; Runkel et al., 2000; Shannon et al., 2000; Iwasa et al., 2001; Hahn et al., 2003) . In the present work, we examined a group of these uncharacterized SNPs, most of which were detected in populations with cardiovascular phenotypes. (Fig. 1 , white-filled circles; Table 1 ). Seven of these SNPs, encoding the amino acid changes N292T, V356L, A369P, N375S, K463R, F528C and Y548H, were identified in a study of both Africans and Americans with Northern European ancestry with blood pressure measures in the upper and lower 2.5 th percentile using high density microarray chips . R121Q was found in a study of Japanese patients with long QT syndrome and was identified in both the control and long QT groups . I549T has been observed by several groups in populations of Asian and European ancestry and is deposited at dbSNP, the SNP database at the National Center for Biotechnology and Informatics (NCBI). These SNPs have been validated by observance of the minor allele in more than one chromosome and/or by multiple independent submissions and Table 1 lists their estimated frequencies (dbSNP; Iwasa et al., 2001 ). Our laboratory, using denaturing high performance liquid chromatography (DHPLC) followed by dideoxy sequencing confirmation, identified V244I in one individual with no defined phenotype. These SNPs occur at amino acids with extremely high conservation among NETs of various species as well as among NETs, DATs and serotonin transporters (SERTs) ( Table 2 ). The variants occur throughout the transporter, in both transmembrane domains (TMs) and loop regions (Figure 1 ). Site-directed mutagenesis was used to generate these SNPs in the hNET cDNA in the expression vector, pcDNA3.
This article has not been copyedited and formatted. The final version may differ from this version. hNET at levels comparable to hNET, whereas the 110 kDa form was essentially absent in total lysates and in the biotinylated fraction ( Fig. 2A and B ; Fig. 3A and B). F528C demonstrated a 22% increase in total lysate levels of the 110 kDa protein and a 35%, increase in 110 kDa surface levels ( Fig. 2A and B ; Fig. 3A and B). Total and surface levels of the 110 kDa form of R121Q
were 83.8±4.1 and 72.1±5.9 of hNET, respectively, with surface levels significantly different from hNET ( Fig. 2A and B ; Fig. 3A and B). Y548H expressed surface levels of the 110 kDa form that were 71.7±10.6 of hNET, a decrease that did not reach significance ( Fig. 2B; Fig. 3B ).
This article has not been copyedited and formatted. The final version may differ from this version. and 110 kDa forms, creating a smeared appearance on blots ( Fig. 2A) . The 110 kDa form of N292T in total lysate was 20.0±12.9 of hNET, although this value is difficult to estimate due to the continuous nature of the distribution of N292T protein. Interestingly, the biotinylated fraction reveals that much of the anomolous N292T remains intracellular whereas the 110 and 54 kDa forms are expressed on the surface, as well as the nonglycosylated 46 kDa form ( Fig 2B) .
The surface levels of the 110 kDa form are decreased to levels 50.7±13.7 of hNET whereas there was a large increase in the surface expression of the 54 kDa form ( Fig 2B; Fig 3B) . Finally, there was a significant decrease in I549T protein in surface fractions not evident in totals ( Fig. 2 and 3). hNET, respectively, changes that reached significance for the decrease in DA transport ( Fig. 5A and B).
We also tested the effect of hNET variants on the ability of transporter inhibitors to compete for [ 3 H]NE transport, targeting cocaine and desipramine as a prototypical psychostimulant and tricyclic antidepressant, respectively. In general only modest shifts in K I values were observed. One exception was F528C, which demonstrated a significant increase in the K I value for desipramine competition of NE uptake, losing potency by approximately 8-fold (4.7 ± 0.6 vs. 40.9 ± 6.0 nM; F 9,30 = 24.50; p<0.001.
The changes in F528C and R121Q expression levels coupled with substrate-specific transport properties suggested that, in addition to trafficking alterations, there might be compromised regulation by signal transduction mechanisms. A well-studied mechanism of hNET regulation is the PKC-mediated down-regulation that occurs in response to receptor stimulation or direct activation of PKC with phorbol esters (Apparsundaram et al., 1998) . We therefore tested the ability of the phorbol ester, β−PΜΑ, to down-regulate R121Q and F528C compared to hNET. Thirty min of 100 nM or 1 µM β−PΜΑ decreased [ 3 H]NE uptake by approximately 40% (Fig 6A) . Treatment with either 100 nM or 1 µM β−PΜΑ for 30 min resulted in a significantly greater decrease in transport by R121Q compared to hNET, whereas F528C was unaffected by β−PΜΑ treatment (Fig. 6A) . Incubation with 100 nM β−PΜΑ for 10 min in the presence or absence of PKC inhibitors was performed to examine the specificity of these effects. Ten min β−PΜΑ treatment resulted in a 25% decrease in hNET [ 3 H]NE transport that was completely blocked by 1 µM staurosporine or 1 µM BIM ( Interestingly, there was a trend for PKC inhibitors to increase basal levels of transport for hNET and R121Q, an effect that was significant for the staurosporine-induced increase in uptake for hNET (Fig. 6B) . This suggests the presence of tonic regulation of hNET in COS-7 cells that can be relieved by staurosporine. Interestingly, F528C showed no such effect of PKC inhibitors on basal transport, again indicating the insensitivity of F528C to regulation by PKC-linked pathways.
The heterozygous nature of hNET SNPs coupled with evidence of oligomer formation by neurotransmitter transporters compelled us to examine the influence of coexpression of hNET variants on hNET. Variants that exhibited altered processing and trafficking of transporter protein, R121Q, F528C, N292T and A369P, were each cotransfected with an equal amount of HA-tagged hNET followed by cell-surface biotinylation and Western blot analysis. Both N292T
and A369P exhibited marked effects on hNET expression when cotransfected (total 54 kDa form, F (4,14) = 5.61; p < 0.05; surface 54 kDa form, F (4,14) = 16.58; p < 0.001; surface 110 kDa form, F (4,14) = 12.05; p < 0.001; total 110 kDa F (4,13) = 10.39; p < 0.01). N292T produced a dramatic decrease in total hNET expression of both 54 and 110 kDa forms and greatly diminished surface expression ( Fig. 7A-D) . A369P also diminished total and surface expression of hNET ( Fig. 7A-D In order to evaluate a potential correlation of functional effects with amino acid substitution of each variant, we examined the BLOSUM62 scores of the hNET SNPs. The BLOSUM62 is a scoring matrix that infers protein function for amino acid substitutions (Henikoff and Henikoff, 1992) . In a study that examined gene mutations in the organic cation transporter, OCT1, Leabman and coworkers (2003) predicted that substitutions at residues conserved in all members of mammalian OCT1 orthologs would be more deleterious than those at evolutionarily unconserved residues (Leabman et al., 2003) . The majority of OCT1 mutations at conserved residues decreased function whereas none of the unconserved changes affected function. Furthermore, the BLOSUM62 scores were more negative (evolutionarily unfavorable) for the variants that decreased function and most with non-negative scores exhibited normal function. When the hNET SNPs evaluated in the present study were divided into two groups, one with those found to exert effects on protein expression, substrate transport, inhibitor binding or regulation by PKC (R121Q, A369P, N292T, F528C, Y548H and I549T) and a second having no effect on these measures (V244I, V356L, N375S and K463R), the group of variants conferring functional changes had significantly lower BLOSUM62 scores, -1.14 ± 0.28, than those deemed to have no effects on function, 1.75 ± 0.48 (p < 0.05; Student's t-test, 2-tailed).
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DISCUSSION
Although it is likely that complex disorders result from multiple gene and environmental influences, candidate gene approaches remain attractive when a strong argument can be advanced for the role of a gene in disease, particularly when endophenotypes are examined. We previously identified a nonfunctional, dominant-negative hNET mutation that contributes to a phenotype of Orthostatic Intolerance, tachycardia and elevated plasma NE levels (Shannon et al., 2000; Hahn et al., 2003) . Most of the SNPs in the present study were also identified in extreme blood pressure or long QT syndrome Iwasa et al., 2001 ). The present results reveal striking effects of these naturally-occurring SNPs on transporter protein expression, substrate transport, antagonist interaction and regulation by kinase-mediated signaling pathways. The use of selective phenotypes should continue to reveal hNET variants with functional consequences that, though they may be limited to a small number of cases or families, could greatly contribute to phenotypes in those individuals.
Among the hNET variants evaluated in the present study, V244I, V356L, N375S, and K463R, had little effect on hNET expression levels or transport of NE and DA, and could represent variation retained in the population due to a lack of negative selection pressure, as evidenced by the positive BLOSUM62 scores of this group and the presence of alternate amino acids at several of these positions in NET of other species (Table 2) . Other amino acids substitutions at these positions, however, have revealed some functional impact. Whereas the extracellular loop 4 variant, N375S, was without effect, N375P increases uptake 2-fold (Roubert et al., 2001) . Similarly, the engineered mutant V356S demonstrates an increase in DA uptake, and a decreased affinity for nortriptyline and desipramine, whereas the naturally-occurring polymorphism V356L did not differ in transport or antagonist affinity.
This article has not been copyedited and formatted. The final version may differ from this version. More than half of the SNPs examined resulted in demonstrable changes in expression, activity, binding or regulation, and, moreover, these SNPs correlated with negative BLOSUM62 scores, indicating unfavorable substitutions. A369P generated the most dramatic effect, revealing a complete lack of transport of NE and DA that was accompanied by a total loss of the surface 110 kDa protein. The 54 kDa form of A369P was expressed on the surface, yet this species was nonfunctional. As we detected minimal accumulation of the immature form of A369P as well as a form migrating at a molecular weight higher than the 110 kDa form that we suspect represents intracellular aggregates, A369P is likely a misfolded protein that is targeted for degradation following exit from the ER, a pattern similar to that observed for the hNET A457P mutation (Hahn et al., 2003) . Interestingly, an hNET mutant of multiple residues, that incorporates amino acids close to A369 in extracellular loop 4, also does not transport (Roubert et al., 2001) pointing to an important role of extracellular loop 4 in transport biosynthesis and function.
Two of the mutants, Y548H and N292T displayed a graded loss of both DA and NE transport. Transport deficits of N292T were similar in degree to reductions in levels of the 110 kDa form, indicating that the 54 kDa form, which demonstrated increased surface expression, is not functional. Interestingly, a triple mutation in the third extracellular loop that includes an N292R substitution exhibited a 7-fold increased capacity for DA (Roubert et al., 2001 ). Y548H, located in extracellular loop 6, reduced both NE and DA uptake and surface transporter by approximately 20%. I549T also demonstrated a decrease in protein, but not in transport. The disparity between these measures for I549T remains to be clarified in future studies, but its proximity to Y548 suggests a sensitivity of this region of the transporter to substitutions.
This article has not been copyedited and formatted. The final version may differ from this version. The variants discussed thus far that affected transport, A369P, N292T and Y548H, are located in extracellular loops 3-6, and these loops, as well as proximal TMs, have been implicated in transport function. Studies of DAT/NET chimeras suggest that the region spanning TMs 4-9 are critical for substrate translocation (Buck and Amara, 1994) . Chimeras of SERT containing the NET extracellular loops 4, 5, or 6 retain antagonist selectivity but demonstrate greatly reduced transport activity (Smicun et al., 1999 (Barker et al., 1994) . Similar to F528C, S545A in TM 11 of SERT, corresponding to S525 in hNET, increases the V MAX for serotonin transport and decreases the binding affinity for the tricyclic antidepressant, imipramine (Sur et al., 1997) . Furthermore, a single F in this region directs potency of hSERT for tricyclic antidepressants (Barker and Blakely, 1996) . In contrast, F530A in rat DAT, corresponding to F528 in hNET, demonstrates little effect on expression levels, yet transport activity is reduced by greater than 90% (Lin et al., 1999) . To the extent that F528C may be enriched in an extreme blood pressure phenotype, it could influence tricyclic treatment response in such individuals.
Taken together, our data and the results of mutational analyses support the involvement of This article has not been copyedited and formatted. The final version may differ from this version. The ability of variants R121Q and F528C to selectively confer changes to NE versus DA transport has precedent in other studies of mutations that produce a substrate-selective impact on transport. For example, species differences between drosophila and human SERTs in binding and transport affinities for substituted tryptamines, but not serotonin, can be closely recapitulated by the single mutation, Y95F, in human SERT (Adkins et al., 2001 ). Studies of rat and human SERT chimeras indicate that TM 11 and 12 of human SERT account for the difference in potency of d-amphetamine relative to rat SERT, whereas serotonin recognition is unaffected (Barker et al., 1994) . Differences in substrate utilization by hNET variants suggest a potential impact of variants on the balance of catecholamine neurotransmission in areas of the central nervous system where dual innervation by NE and DA occurs. In the prefrontal cortex, where This article has not been copyedited and formatted. The final version may differ from this version. both NE and DA fibers are present, released DA is cleared from the extracellular space by NET (Gresch et al., 1995) . The therapeutic effect of selective NET blockers in the treatment of ADHD may lie in their ability to elevate both NE and DA.
The observation that F528C was insensitive and R121Q more sensitive to β−PΜΑ suggests that similar mechanisms may underlie differences observed in both basal and regulated transport. F528C was insensitive to staurosporine inhibition, supporting that PKC activity present in untreated cells may play a part in differences we observe in basal transport. In addition, PKC-induced down-regulation results not only in a decrease in hNET V MAX but also influences NET intrinsic activity (Apparsundaram et al., 1998; Sung et al., 2003) and such a function may play a role in effects observed on hNET variants in the present study.
A369P and N292T both decreased total and surface levels of hNET supporting growing evidence that intracellularly-retained or mistargeted mutants exert dominant-negative effects to decrease surface expression and activity of wild type transporters facilitated by formation of oligomeric complexes (Hahn et al., 2003; Sitte et al., 2004) . Elevated levels of unglycosylated and anomolously glycosylated N292T may additionally saturate synthesis and glycosylation processes. That N292T accumulates in lower molecular forms, whereas it greatly diminishes cotransfected hNET, suggests that N292T may be a more stable protein. The normal core glycosylation but defect in late-stage glycosylation exhibited by A369P is similar to that of our previously described variant, A457P, a variant that restricts hNET surface expression and has a dominant-negative impact on hNET transport (Hahn et al., 2003) . It was somewhat surprising that neither N292T nor A369P diminished transport to an extent that might be predicted from the effect on hNET protein. A457P exhibits measurable surface expression of a nonfunctional 110 kDa form that may contribute to its dominant-negative influence on transport. Additionally, the This article has not been copyedited and formatted. The final version may differ from this version. with our previous data and that of other groups, support that dominant-negative associations with variants can occur at early stages of transporter biosynthesis to influence hNET biosynthetic progression, whereas evidence of functional interactions between subunits at the level of the plasma membrane remain to be explored further.
The present data reveal striking influences of naturally-occurring hNET coding variants on hNET function that may indeed contribute to in vivo function, as suggested by their discovery in cardiovascular phenotypes. In this regard, a recently identified SERT variant demonstrates both faster translocation and altered response to second messengers in vitro and can be tracked in carriers within two families presenting with complex psychiatric profiles, including obsessive compulsive disorder and social phobia (Kilic et al., 2003) . It will be important to examine the expression of hNET variants in transfected neuronal culture, in which depolarization, second messengers, and voltage-sensitive transporter-associated currents likely all play a role in regulating transporter activity (Galli et al., 1998; Savchenko et al., 2003) . Additionally, genetically modified mice bearing functional variants should facilitate the analysis of systemslevel questions of transporter response in the face of neuronal excitability and second messenger activation, the influence of substrate selectivity, and the impact of these factors on behavior.
This article has not been copyedited and formatted. The final version may differ from this version. Methods. 24 h later cells were incubated in sulfo-NHS-SS-biotin followed by extraction in RIPA buffer containing protease inhibitors. Aliquots containing equal amounts of protein were taken from each sample for total hNET and from the remaining sample aliquots of equal amounts of protein were extracted with streptavidin beads as described in Methods. Blots were probed with a monoclonal antibody to hNET (NET-17-1) followed by a goat anti-mouse HRPconjugated secondary antibody and chemiluminescent detection. Arrows indicate different molecular weight forms of hNET described in text. Molecular weights indicated are from prestained standards run in parallel and are noted in kDa.
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.05 compared to hNET of corresponding molecular weight form.
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